stocktrademan
9 years ago
$ICCC recent news/filings
bullish 7.40
gap up on earnings
hidden bullish divergence
continuation
above average green volume
## source: finance.yahoo.com
Thu, 12 Nov 2015 21:08:39 GMT ~ IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
read full: http://biz.yahoo.com/e/151112/iccc8-k.html
*********************************************************
Thu, 12 Nov 2015 21:05:00 GMT ~ ImmuCell Announces Results for Third Quarter of 2015
[Marketwired] - ImmuCell Corporation , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced ...
read full: http://finance.yahoo.com/news/immucell-announces-results-third-quarter-210500368.html
*********************************************************
Thu, 12 Nov 2015 12:07:03 GMT ~ Q3 2015 ImmuCell Corp Earnings Release - After Market Close
read full: http://biz.yahoo.com/research/earncal/20151112.html?t=iccc
*********************************************************
Tue, 10 Nov 2015 20:46:10 GMT ~ 11-5-2015 “ImmuCell to Announce Third Quarter 2015 Financial Results”
[at noodls] - 6bc0b971-bbb6-44b0-aade-21db8c59004f.pdf ImmuCell FOR IMMEDIATE RELEASE: ImmuCell to Announce Third Quarter 2015 Financial Results Conference Call Scheduled for Thursday, November 12, 2015 at 4:30 PM EST ...
read full: http://www.noodls.com/view/4EEDC0DA5D37CA5423DA253B28034D61598E38C5
*********************************************************
Thu, 05 Nov 2015 13:00:00 GMT ~ ImmuCell to Announce Third Quarter 2015 Financial Results
[Marketwired] - ImmuCell Corporation , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report third ...
read full: http://finance.yahoo.com/news/immucell-announce-third-quarter-2015-130000704.html
*********************************************************
$ICCC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ICCC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ICCC/company-info
Ticker: $ICCC
OTC Market Place: Not Available
CIK code: 0000811641
Company name: ImmuCell Corp.
Incorporated In: DE, USA
$ICCC share structure
## source: otcmarkets.com
Market Value: $22,607,252 a/o Nov 13, 2015
Shares Outstanding: 3,055,034 a/o Aug 10, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.1
$ICCC extra dd links
Company name: ImmuCell Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICCC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICCC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICCC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/news - http://finance.yahoo.com/q/h?s=ICCC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICCC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICCC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICCC
DTCC (dtcc.com): http://search2.dtcc.com/?q=ImmuCell+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ImmuCell+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ImmuCell+Corp.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICCC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000811641&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICCC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICCC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICCC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICCC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICCC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICCC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICCC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICCC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICCC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICCC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICCC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICCC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICCC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICCC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICCC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICCC
$ICCC DD Notes ~ http://www.ddnotesmaker.com/ICCC
Drmicrocap
11 years ago
ImmuCell Announces Increase in Product Sales and Other Annual Financial Results
.
Marketwired
ImmuCell Corporation
February 13, 2014 8:00 AM
.
.
..
.
.
PORTLAND, ME--(Marketwired - Feb 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.
During the three-month period ended December 31, 2013, product sales increased by 9.7%, or $138,000, to $1,559,000 in comparison to $1,421,000 during the same period in 2012. During the twelve-month period ended December 31, 2013, product sales increased by 11.5%, or $617,000, to $6,007,000 in comparison to $5,390,000 during the same period in 2012.
"We have now increased product sales during the last six consecutive quarters and for twelve of the last thirteen quarters. Sales of First Defense® and related product line extensions increased by 16.5% during the fourth quarter and 14.4% during the year ended December 31, 2013," commented Michael F. Brigham, President and CEO.
The net operating (loss) was ($210,000) during the three-month period ended December 31, 2013, in contrast to a net operating income of $12,000 during the same period in 2012. The net (loss) was ($151,000), or ($0.05) per share, during the three-month period ended December 31, 2013, in comparison to a net (loss) of ($17,000), or ($0.01) per share, during the same period in 2012.
Net operating (loss) was ($20,000) during the twelve-month period ended December 31, 2013, in contrast to net operating income of $245,000 during the same period in 2012. Net income was $117,000, or $0.04 per share, during the twelve-month period ended December 31, 2013, in comparison to net income of $90,000, or $0.03 per share, during the same period in 2012.
Regarding the fourth quarter loss, Mr. Brigham added, "During the fourth quarter, we incurred approximately $110,000 in expenses as we initiated our planned investment in a Nisin production plant for Mast Out®. Further, we reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold. We expect our gross margin percentage to be more in line with our historical norms during 2014."
Cash, cash equivalents and short-term investments increased by 7%, or $342,000, to $5,255,000 as of December 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $201,000, to $9,396,000 as of December 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,026,000 shares of common stock outstanding as of December 31, 2013.
(Unaudited)
For the Three-Month Periods Ended December 31, For the Twelve-Month Periods Ended December 31,
(In thousands, except per share amounts) 2013 2012 2013 2012
Product sales $ 1,559 $ 1,421 $ 6,007 $ 5,390
Costs of goods sold 951 671 2,947 2,336
Gross margin 608 750 3,060 3,054
Product development expenses 325 234 1,154 918
Selling and administrative expenses 493 503 1,926 1,891
Operating expenses 818 737 3,080 2,809
NET OPERATING (LOSS) INCOME (210 ) 13 (20 ) 245
Other (expenses) revenues, net (43 ) (24 ) 225 (53 )
(LOSS) INCOME BEFORE INCOME TAXES (253 ) (11 ) 205 192
Income tax (benefit) expense (102 ) 6 88 102
NET (LOSS) INCOME $ (151 ) $ (17 ) $ 117 $ 90
Weighted average common shares outstanding:
Basic 3,021 3,019 3,019 3,018
Diluted 3,021 3,019 3,085 3,108
NET (LOSS) INCOME PER SHARE:
Basic $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
Diluted $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
(In thousands) As of December 31, 2013 As of December 31, 2012
Cash, cash equivalents and short-term investments $ 5,255 $ 4,914
Total assets 10,961 11,030
Net working capital 6,632 6,697
Stockholders' equity $ 9,396 $ 9,195
About ImmuCell: ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Contact:
Michael F. Brigham
President and CEO
(207) 878-2770 Ext. 3106
Drmicrocap
11 years ago
ImmuCell Announces Increase in Product Sales and Continued Profitability
MarketwiredPress Release: ImmuCell Corporation – Tue, May 14, PORTLAND, ME--(Marketwired - May 14, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended March 31, 2013.
During the three-month period ended March 31, 2013, product sales increased by 8%, or $130,000, to $1,847,000 in comparison to $1,717,000 during the same period in 2012.
Net operating income was $327,000 during the three-month period ended March 31, 2013, in comparison to net operating income of $281,000 during the same period in 2012. The net income was $204,000, or $0.07 per share, during the three-month period ended March 31, 2013, in comparison to net income of $155,000, or $0.05 per share, during the same period in 2012. The improved financial performance is largely due to increased gross margin from sales of First Defense®.
"In this extremely challenging dairy and beef economy with a record low milk-to-feed price ratio narrowing our customers' profit margins, our product sales increased by 8% and 5% during the three-month and twelve-month periods ended March 31, 2013, respectively," commented Michael F. Brigham, President and CEO. "This sales growth contributed to our continued profitability, while we are actively seeking a partner to help us complete the development and commercialization of Mast Out®."
Cash, cash equivalents and short-term investments increased by 8%, or $392,000, to $5,305,000 as of March 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $219,000, to $9,413,000 as of March 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,019,000 shares of common stock outstanding as of March 31, 2013.
About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Contact:
Michael F. Brigham, President and Chief Executive Officer
(207) 878-2770 Ext. 3106
(Unaudited)
For the Three-Month Periods Ended March 31,
(In thousands, except per share amounts) 2013 2012
Product sales $ 1,847 $ 1,717
Costs of goods sold 793 704
Gross margin 1,054 1,013
Product development expenses 267 248
Sales, marketing and administrative expenses 461 484
Other operating expenses 728 732
NET OPERATING INCOME 326 281
Other revenues (expenses), net 44 (10 )
INCOME BEFORE INCOME TAXES 370 271
Income tax expense 166 116
NET INCOME $ 204 $ 155
Weighted average common shares outstanding:
Basic 3,019 3,016
Diluted 3,084 3,103
NET INCOME PER SHARE:
Basic $ 0.07 $ 0.05
Diluted $ 0.07 $ 0.05
(Unaudited)
As of
March 31, 2013 As of
December 31, 2012
(In thousands)
Cash, cash equivalents and short-term investments $ 5,305 $ 4,914
Total assets 11,111 11,030
Net working capital 7,082 6,697
Stockholders' equity $ 9,413 $ 9,195
.
.
Contact:.
.
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106
DragonBits
13 years ago
Pfizer Won’t Break Up Animal Unit as Lilly Shows Interest in Some Products
QBy Tom Randall and Bob Langreth - Jul 21, 2011 12:24 PM CT .
Pfizer Inc. (PFE), the world’s biggest drugmaker, said it has no plans to break up the company’s animal health unit after Eli Lilly & Co. (LLY) expressed interest in buying some of its products.
Lilly, which had $1.39 billion in sales from animal-health products last year, is monitoring Pfizer’s plans to divest its unit and will pursue assets deemed of interest, Chief Financial Officer Derica Rice said today in a conference call. Pfizer wants a sale or spinoff of the unit and doesn’t foresee breaking it up, said Joan Campion, a company spokeswoman.
Pfizer Chief Executive Officer Ian Read said on July 7 he is divesting the company’s animal health and nutrition units to buy back shares and focus on developing new drugs. The units may fetch $22 billion, according to Seamus Fernandez, an analyst at Leerink Swann & Co. Pfizer’s animal health unit had sales last year of $3.48 billion.
“While we are evaluating a variety of options including a sale, spinoff or other transaction, we believe we will favor one overall option rather than dividing assets and business operations,” Campion said today in an e-mail.
Pfizer’s review of its options for the unit will take 12 to 24 months, Campion said. The company doesn’t plan further announcements about the unit until 2012, she said.
Pfizer shares rose 27 cents, or 1.4 percent, to $20.17 at 1:22 p.m. in New York Stock Exchange composite trading. Lilly rose $1.23, or 3.2 percent, to $39.40, for the biggest intraday gain since May 3.
Evolving Situation
“We will watch how that situation evolves, and if there are some assets that become available that we are interested in, yes, we will pursue them,” Lilly’s Rice said in a conference call with analysts. “It is very early to speculate” what type of transaction Pfizer is seeking, he said.
Lilly isn’t likely to buy the unit outright, Fernandez said in an e-mail. In order to maintain its quarterly dividend of 49 cents a share, which Rice has said Lilly will do, the company would have to issue more stock and risk diluting earnings or use so much cash that it would hurt the company’s credit ratings, Fernandez said. The deal is also unlikely to be approved by antitrust regulators, he said.
“I simply don’t think they are interested, and a $12 billion-plus deal would be a pretty big deal,” Fernandez wrote. If another buyer emerges and faces regulatory hurdles, Lilly might be able to purchase some assets from the acquiring company, he said.
Lilly is interested in expanding its Elanco animal heath unit’s offerings in vaccines and pet products, as well as boosting its presence in Europe, Jeff Simmons, president of the division, said in a June 29 telephone interview. Elanco’s biggest product line is feed additives for cattle and poultry.
“We are going to be opportunistic in animal health,” Simmons said. “We are looking for additional assets. We are not interested in acquiring for the sake of acquiring; it has got to have a strategic element.”
To contact the reporters on this story: Tom Randall in New York at trandall6@bloomberg.net; Robert Langreth in New York at rlangreth@bloomberg.net
DragonBits
13 years ago
Sell Stocks, Buy Cows: Casey
Feeling lost in your quest for fresh money-making opportunities these days? Well, you're not alone. Even a globe-trotting speculator like Doug Casey, who's namesake firm, Casey Research, prides itself on being "Intensely Curious, Focused on Facts" says there's just aren't many good places to hide anymore.
"Good investment ideas are not thick underfoot these days" says Casey, adding that "the next few years will be marvelous from the point of view of a speculator, but horrible for the average guy." Casey's definition of a speculator is not a gambler or a trader, but rather someone who capitalizes on politically caused distortions in the marketplace, and he's expecting a lot of them. As such, and not surprisingly, Casey loves gold and hates the dollar.
On the former, Casey sees the bull market in gold eventually entering a "mania stage" which he thinks could push it to $5000 an ounce. Even so, he says the recent run-up to $1500 is cause for "hesitation," yet still broadly advises that people "should own a lot of gold."
As for the dollar, and major currencies in general, his commentary is more caustic, as he blasts the long-term washout that looms as a result of "trillions of currency units that all these stupid governments are creating."
Casey openly does not like to link his predictions with time lines. He says in the years to come, the dollar will trade to its intrinsic value (as in -- be worth the paper it's printed on), which "will be quite ugly." This despite his belief that "the EU is going to fall apart and euro will cease to exist" within the next 5 to 10 years.
And there's more sunshine where that came from.
Casey says "your biggest single risk is political. You must diversify so all your money isn't in the control of one government." He says he's heavily diversified outside of the U.S., and "bought a lot of agricultural land in Argentina." True to his word, Casey now spends most of his time living and investing in South America.
So if you already own gold and you're not moving to South America, what else looks good?
"I am a big believer in cattle. I recommend building herds, both dairy and beef" because he says it's probably the cheapest major market he can think of. Interestingly, he has no interest in trading cattle (futures).
And if you're not quite ready to embrace farming, he has one other suggestion: "I would be short bonds. You can make a killing doing that."
So there you have it. Just when you thought your pessimism could not be eclipsed, Doug Casey comes forth and sets a new benchmark for bearishness.
http://finance.yahoo.com/blogs/breakout/sell-stocks-buy-cows-casey-152817594.html?sec=topStories&pos=7&asset=&ccode=
DragonBits
14 years ago
New mastitis treatment may offer alternative to
The important part of this for me was the current market for antibiotics for mastis. I have seen this 40-50 million number before. Of course the market ICCC is going for is sub-clinical mastis, which is potentially larger and has no treatment for.
New mastitis treatment may offer alternative to antibiotics
Agricultural Research, Feb, 2006 by Jan Suszkiw
A new weapon could be on tap for fighting bacteria that cause mastitis, an inflammatory udder disease of dairy cows costing around $2 billion annually in animal and milk-production losses.
In trials at ARS's Bovine Functional Genomics Laboratory, Beltsville, Maryland, scientists Max Paape and Douglas Bannerman showed that injecting the cows' mammary glands with the sugar Poly-x reduced mastitis infections at about one-twelfth the cost of antibiotics.
The sugar, a type known as a "polysaccharide," occurs naturally in the cell walls of certain yeasts. But when administered to nonlactating ("dry") dairy cows, the polysaccharide serves as a kind of biochemical bugle call that mobilizes the animals' immune system, especially to produce bacteria-killing 1 white blood cells.
"Previous work at Beltsville indicated that increasing the cell count in milk will prevent infection," says Paape, a dairy scientist. "Poly-x increases the cell count in dry-cow secretions for the first 5 days of the dry period, thus preventing infection by bacteria."
Today's mastitis-control programs often use several measures, like diagnostic testing, sanitation, herd separation, animal culling, teat dips, and antibiotic treatment. For conventional dairy operations, antibiotics use can be expensive, costing about $10 a cow, or $45 million nationwide, Paape estimates. The practice is also controversial, with concerns focusing on the potential for environmental contamination and the emergence of antibiotic-resistant bacteria.
Paape and Bannerman see some advantages to using Poly-x as a natural alternative--the lack of residues being one. Another is the expense. A tube of antibiotic costs around $2.50. By comparison, the ingredient cost for an experimental Poly-x treatment is only 20 cents.
http://findarticles.com/p/articles/mi_m3741/is_2_54/ai_n16069030/
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
ClayTrader
5 years ago
$Pistol Pete$
9 years ago
JD400
11 years ago
Penny Roger$
13 years ago
surf1944
13 years ago
